COHANCE - Cohance Lifesciences

Cohance Lifesciences

COHANCE · Pharma > Pharmaceuticals & Drugs · Chairman: Venkateswarlu Jasti · MD: Venkateswarlu Jasti · Listing date: March 10, 2020 · Employees: 1114 · Hyderabad · http://www.suvenpharm.com

Stock Price vs Company Growth

1.0%

1.4%

58.3%

44.3%

30.8%

53.8%

1.3%

all

19.4%

🤔 How to analyze this graph?

Last Traded Price

₹ 490 1.0%

268

515

Company Overview

Sales

2,051 Cr

Growth: 17.7%

Profit after Tax

202 Cr

Growth: -36.6%

Mid Cap

18,732 Cr

P/E: 85.1x

Industry P/E: 30.4x

Fundamentals

Sales (Cr)	₹ 2,051
Growth	17.7%
EBITDA	19.6%
P/S	9.1x
Dividend	0.0%
P/E	85.1x
Book Value	₹ 48.9
PEG Ratio	4.7x
ROE	11.3%
P/B	9.8x

Shareholding Pattern

Institutions

Uti Small Cap Fund

2.17 %

L And T Mutual Fund Trustee Ltd-L And T Mid Cap Fund

1.95 %

Promoters

Jasti Property And Equity Holdings Private Limited(Initscapacityassoletrusteeofjastifamilytrust)

60.0 %

Others

Rambabu Chirumamilla

2.14 %

Qualified Institutional Buyer

0.7 %

Iepf

0.14 %

Increase Decrease No change

Company Profile Detailed

The company is a fully integrated global CDMO, partnering with leading innovators across the entire product lifecycle- from route scouting and early development to commercial manufacturing. With advanced capabilities in oligonucleotides, bioconjugation and complex small molecules, it addresses some of the most challenging chemistries in the industry.

Belongs to (29 Indices) view more

Investors (34)

abhishek...

landt.mu...

marshall...

Followers (4)

ramakris...

krishna5...

venkatja...